CJRB 204
Alternative Names: CJRB-204; MRx-0001Latest Information Update: 19 Sep 2023
At a glance
- Originator 4D Pharma PLC
- Developer 4D Pharma PLC; CJ Bioscience
- Class Anti-inflammatories; Antiasthmatics; Bacteria
- Mechanism of Action Bacteria replacements; Microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Inflammatory bowel diseases
- Discontinued Allergic asthma
Most Recent Events
- 19 Sep 2023 Discontinued - Preclinical for Allergic asthma in United Kingdom (PO) (CJ Biosciences pipeline, September 2023)
- 19 Sep 2023 Preclinical trials in Inflammatory bowel diseases in South Korea (PO) (CJ Biosciences pipeline, September 2023)
- 27 Mar 2023 CJ Biosciences acquires CJRB 204 from 4D Pharma (CJ Biosciences pipeline, September 2023)